Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nifuroxazide is an oral nitrofuran antibiotic used primarily for the treatment of colitis and diarrhea, including infectious and traveler's diarrhea. It acts as a broad-spectrum intestinal anti-infective agent by inhibiting bacterial enzymes essential for cellular processes, thereby exerting its antimicrobial effects. In addition to its antibacterial activity, nifuroxazide has demonstrated antiparasitic properties against organisms such as Giardia lamblia, Cryptosporidium parvum, and Schistosoma mansoni. Recent research suggests potential anticancer, anti-inflammatory, antioxidant, and immunomodulatory activities mediated through inhibition of Signal transducer and activator of transcription 3 (STAT3) signaling pathways and other molecular targets (such as NF-kB and TLR4). The drug is administered orally in capsule or suspension form[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nifuroxazide.